Overview

Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
0
Participant gender:
All
Summary
Determination of the effect of Neugranin on the duration and severity of severe neutropenia in subjects receiving doxorubicin in combination with docetaxel.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Treatments:
Docetaxel
Doxorubicin
Liposomal doxorubicin
Criteria
Inclusion Criteria:

- Breast cancer patients scheduled to receive the AT regimen (doxorubicin/ docetaxel)

Exclusion Criteria:

- Subjects may have received no more than 1 prior chemotherapy regimen (including
adjuvant therapy if given within the last 12 months)